Literature DB >> 24999285

Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology.

Mengye Guo1, Jeffrey T Yap2, Annick D Van den Abbeele3, Nancy U Lin4, Armin Schwartzman5.   

Abstract

F-18-Fluorodeoxyglucose positron emission tomography (FDG-PET) has been used to evaluate the metabolic response of metastatic brain tumors to treatment by comparing their tumor glucose metabolism before and after treatment. The standard analysis based on regions-of-interest has the advantage of simplicity. However, it is by definition restricted to those regions and is subject to observer variability. In addition, the observed changes in tumor metabolism are often confounded by normal changes in the tissue background, which can be heterogenous. We propose an analysis pipeline for automatically detecting the change at each voxel in the entire brain of a single subject, while adjusting for changes in the background. The complete analysis includes image registration, segmentation, a hierarchical model for background adjustment and voxelwise statistical comparisons. We demonstrate the method's ability to identify areas of tumor response and/or progression in two subjects enrolled in a clinical trial using FDG-PET to evaluate lapatinib for the treatment of brain metastases in breast cancer patients.

Entities:  

Keywords:  Statistical parametric mapping; false discovery rate; mixture distribution; multiple testing

Year:  2014        PMID: 24999285      PMCID: PMC4078880          DOI: 10.1002/sta4.53

Source DB:  PubMed          Journal:  Stat        ISSN: 0038-9986


  16 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

Authors:  L Sokoloff; M Reivich; C Kennedy; M H Des Rosiers; C S Patlak; K D Pettigrew; O Sakurada; M Shinohara
Journal:  J Neurochem       Date:  1977-05       Impact factor: 5.372

Review 3.  Cancer's molecular sweet tooth and the Warburg effect.

Authors:  Jung-whan Kim; Chi V Dang
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

4.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

5.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Nancy U Lin; Lisa A Carey; Minetta C Liu; Jerry Younger; Steven E Come; Matthew Ewend; Gordon J Harris; Elizabeth Bullitt; Annick D Van den Abbeele; John W Henson; Xiaochun Li; Rebecca Gelman; Harold J Burstein; Elizabeth Kasparian; David G Kirsch; Ann Crawford; Fred Hochberg; Eric P Winer
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

6.  Breast cancer: metastatic patterns and their prognosis.

Authors:  V Patanaphan; O M Salazar; R Risco
Journal:  South Med J       Date:  1988-09       Impact factor: 0.954

Review 7.  The lessons of GIST--PET and PET/CT: a new paradigm for imaging.

Authors:  Annick D Van den Abbeele
Journal:  Oncologist       Date:  2008

8.  Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.

Authors:  Roy S Herbst; Angela M Davies; Ronald B Natale; Thao P Dang; Joan H Schiller; Linda L Garland; Vincent A Miller; David Mendelson; Annick D Van den Abbeele; Yulia Melenevsky; Daniel J de Vries; David A Eberhard; Benjamin Lyons; Stuart G Lutzker; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

Review 10.  Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

Authors:  Annick D Van den Abbeele; Ramsey D Badawi
Journal:  Eur J Cancer       Date:  2002-09       Impact factor: 9.162

View more
  2 in total

1.  Method for detecting voxelwise changes in fluorodeoxyglucose-positron emission tomography brain images via background adjustment in cancer clinical trials.

Authors:  Lei Qin; Armin Schwartzman; Keisha McCall; Nezamoddin N Kachouie; Jeffrey T Yap
Journal:  J Med Imaging (Bellingham)       Date:  2017-06-01

2.  Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans.

Authors:  E Wolsztynski; F O'Sullivan; J O'Sullivan; J F Eary
Journal:  Stat Med       Date:  2016-12-18       Impact factor: 2.373

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.